达格列净联合DPP-4抑制剂用于2型糖尿病临床治疗的价值分析  

Analysis of the Value of Dapagliflozin Combined with Dpp4 Inhibition for the Treatment of Type 2 Diabetes Mellitus in Clinical Therapy

作　　者：林永阳 张妩云 郑兰秀 LIN Yongyang;ZHANG Wuyun;ZHENG Lanxiu(Department of Pharmacy,Fuzhou Economic and Technological Development Zone Hospital,Fuzhou,Fujian Province,)

机构地区：[1]福州经济技术开发区医院药剂科,福建福州350015

出　　处：《糖尿病新世界》2024年第5期15-18,共4页Diabetes New World Magazine

摘　　要：目的分析2型糖尿病(Type 2 Diabetes Mellitus,T2DM)在达格列净联合二肽基肽酶-4(Dipeptidyl Pepti-dase-4,DPP-4)抑制剂治疗下的实际改善效果。方法选取2020年2月—2023年3月福州经济技术开发区医院100例T2DM患者作为研究对象,根据既往治疗方案分成参照组(50例,二甲双胍+DPP-4抑制剂)和观察组(50例,二甲双胍+DPP-4抑制剂+达格列净),比较药物不良反应率、血肌酐(Serum Creatinine,Scr)、血尿酸(Blood Uric Acid,BUA)、胆固醇(Total Cholesterol,TC)、三酰甘油(Triglyceride,TG)、餐后2 h血糖(2 h Post-prandial Plasma Glucose,2 hPG)、空腹血糖(Fasting Plasma Glucose,FPG)指标。结果治疗后观察组患者BUA为(302.56±38.28)μmol/L,TC为(4.29±0.74)mmol/L,TG为(1.43±0.44)mmol/L,2 hPG为(9.32±0.42)mmol/L,FPG为(6.42±0.15)mmol/L,低于参照组,差异有统计学意义(t=2.023、5.235、2.284、6.515、26.524,P均<0.05);两组Scr指标及药物不良反应率对比,差异无统计学意义(P均>0.05)。结论达格列净与DPP-4抑制剂联合应用于T2DM治疗中效果优良。Objective To analyze the actual improvement effect of type 2 diabetes mellitus(T2DM)treated with dapa-gliflozin combined with dipeptidyl peptidase-4(DPP-4)inhibitor.Methods 100 cases of T2DM patients were se-lected as study objects in Fuzhou Economic and Technological Development Zone Hospital from February 2020 to March 2023,and were divided into a reference group(50 cases of metformin+DPP-4 inhibitor)and an observation group(50 cases of metformin+DPP-4 inhibitor+dapagliflozin)according to the previous treatment programs.The rate of adverse drug reactions,serum creatinine(Scr),blood uric acid(BUA),total cholesterol(TC),triglyceride(TG),2 h postprandial plasma glucose(2 hPG),fasting plasma glucose(FPG)were compared.Results After treatment,BUA[(302.56±38.28)μmol/L],TC[(4.29±0.74)mmol/L],TG[(1.43±0.44)mmol/L],2 hPG[(9.32±0.42)mmol/L],FPG[(6.42±0.15)mmol/L]of patients in the observation group were lower than those in the reference group,the differences were statistically significant(t=2.023,5.235,2.284,6.515,26.524,all P<0.05).There were no statistically significant differences in the Scr index and the rate of adverse drug reactions between two groups(both P>0.05).Conclusion Dapagliflozin combined with DPP-4 inhibitor has excellent effect in T2DM treatment.

关 键 词：2型糖尿病 达格列净 DPP-4抑制剂 血糖指标 肾功能 血脂指标 

分 类 号：R59[医药卫生—内科学]